<DOC>
	<DOCNO>NCT02632474</DOCNO>
	<brief_summary>The purpose study determine efficacy combination low dose Tenofovir , Efavirenz Lamivudine treat HIV-infection .</brief_summary>
	<brief_title>ART Drug Dosage Adjustment HIV-infected Population</brief_title>
	<detailed_description>The feedback system control ( FSC ) technique develop rapidly identify optimal combination therapeutic purpose . Low dose TDF+3TC+EFV combination test vitro study FSC show high efficacy investigator apply human optimize ART combination .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV antibody positive HIV RNA 10*E5 copies/ml CD4 T cell count 200 cells/ml Provision write informed consent HIV genotyping resistant investigate drug Pregnant , breastfeeding , lactate Any serious active medical psychiatric illness , opinion Investigator , would interfere treatment , assessment , compliance protocol , subject safety . This would include active clinically significant renal , cardiac , pulmonary , vascular , metabolic ( thyroid disorder , adrenal disease ) illness , malignancy Medical psychiatric condition occupational responsibility may preclude compliance protocol Laboratory blood value : Haemoglobin &lt; 7.0 grams/decilitre ( g/dL ) Neutrophil count &lt; 500/mm3 Platelet count &lt; 50,000/mm3 Aspartate aminotransferase Alanine transaminase &gt; 5 time Upper Limit Normal ( ULN ) Subjects estimate creatinine clearance &lt; 50 mL/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Efavirenz</keyword>
</DOC>